Trial | NCT01019408  Report issue

Title

Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan
Clinical Trial of Extended-dose Chloroquine Versus Standard Chloroquine Treatment for Resistant Falciparum Malaria Among Afghan Refugees in NWFP Pakistan

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    163
The purpose of this study was to provide stronger evidence for extended-dose chloroquine treatment of falciparum-positive Afghan refugees in Northwest Frontier Province (NWFP), Pakistan or justification for discontinuation of the policy.
To determine whether extended-dose chloroquine provided better cure rates and fewer recrudescences than standard chloroquine treatment among Afghan refugees, 163 falciparum patients from three Afghan refugee camps were recruited into 3-day (CQ 25mg/kg) or 5-day (CQ 40mg/kg) treatment arms and followed for up to 60 days.
Study Started
Nov 30
1993
Primary Completion
Jan 31
1995
Study Completion
Jan 31
1995
Last Update
Nov 25
2009
Estimate

Drug Chloroquine

Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan

  • Other names: CQ

CQ25 Active Comparator

Falciparum positive patients receiving standard 3-day treatment course of CQ 25mg/kg.

CQ40 Active Comparator

Falciparum positive patients receiving a 5-day treatment course of CQ 40 mg/kg.

Criteria 

Inclusion Criteria:

slide-confirmed infection with P. falciparum only
initial parasite density of 1000-100,000 asexual parasites/μl
absence of severe malnutrition
ability to attend stipulated follow-up visits and easy access to facility
informed consent provided by patient or parent/guardian
absence of history of hypersensitivity reactions to CQ

Exclusion Criteria:

infants under six months old
pregnancy or lactation
underlying chronic severe illness
patients with other febrile illnesses
parasitaemia outside the range of 1000-100,000 asexual parasites/µl
severe malaria
No Results Posted